Quanterix Misses Revenue Targets Amid Market Softness
Event summary
- Quanterix reported $32.9M in Q2 2026 revenue, up 34% YoY but below expectations.
- Adjusted EBITDA loss narrowed to $10.0M from $13.7M in the prior year.
- Company recorded a $26.9M goodwill impairment related to Akoya acquisition.
- Cash position stands at $96.9M, with adjusted cash usage of $4.0M in Q2 2026.
The big picture
Quanterix's Q2 results highlight the challenges of navigating a soft market while integrating acquisitions. The company's strategic focus on diagnostics, particularly in Alzheimer’s disease testing, positions it within broader trends toward precision medicine. However, execution risks and market conditions will determine its ability to return to sustained growth.
What we're watching
- Execution Risk
- How Quanterix's restructuring efforts will impact commercial performance in H2 2026.
- Market Dynamics
- Whether the academic and pharmaceutical end markets will improve to meet revised revenue guidance.
- Strategic Focus
- The pace at which Quanterix advances its Alzheimer’s disease testing milestones and FDA roadmap.
Related topics